检索结果-南通市图书馆

Chronic Urticaria Due to Allergy to Wheat Alpha-Amylase Inhibitor Proteins

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Case Reports in Clinical Medicine 2016年第4期5卷 130-133页

作者： Nagore Arruti Oyarzabal Olga Villarreal Balza de Vallejo Nagore Bernedo Belar Maria Teresa Audicana Berasategui Natividad Longo Areso borja Bartolomé servicio de Alergia e Inmunología Clínica Hospital Universitario Araba Vitoria-Gasteiz Spain Bial-Aristegui Laboratories Bilbao Spain

Chronic spontaneous urticaria (CsU) is defined as the spontaneous appearance of wheals, angioedema, or both, for at least 6 weeks, due to known or unknown causes [1]. In some patients who present a CsU with daily or almost daily symptoms a type I allergy could be the underlying cause. We present one adult patient with chronic urticaria who was finally diagnosed as a non-occupational case of IgE-mediated wheat allergy manifested following exposure by 3 different routes: inhalation (rhinitis and bronchial asthma), dermal absorption (contact urticaria) and ingestion (systemic chronic urticaria). We were able to detect the culprit proteins by immunoblotting. serum IgE binds mainly to alpha-amylase/trypsin inhibitors and, to a lesser extent, to other proteins associated with food allergy to grains (e.g. beta-glucanase, serpin, peroxidase). In our opinion, skin prick tests with a food standard battery could help in the etiological diagnosis of chronic urticaria. The identification of responsible allergens could be difficult because only a few complex in vitro techniques allow detecting the allergy to several proteins.

关键词： Alpha-Amylase Inhibitor Wheat Chronic Urticaria Allergy

通过低能耗绝热脉冲和快速螺旋采样实现的神经系统三维核磁共振光谱成像

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国医疗设备 2012年第5期27卷 1-12页

作者： Ovidiu C. Andronesi MDP borja A. Gagoski A. Gregory sorenson 哈佛医学院麻省总医院放射科马蒂诺生物医学成像中心，美国波士顿麻省理工学院电气工程科学学院，美国马萨诸塞州

目的提高三维（3D）核磁共振（MR）光谱成像系统的定位精确度和采样速度。材料与方法本研究所涉及的内容经机构审查委员会（Institutional Review Board）批准并获得患者知情同意。用一台配有32通道头部线圈系统的3T核磁共振成像仪采集... 详细信息

目的提高三维（3D）核磁共振（MR）光谱成像系统的定位精确度和采样速度。材料与方法本研究所涉及的内容经机构审查委员会（Institutional Review Board）批准并获得患者知情同意。用一台配有32通道头部线圈系统的3T核磁共振成像仪采集体模、5位健康的志愿者以及5位胶质母细胞瘤患者的数据。信号激发手段为定位绝热自旋回波聚焦（LAsER），此法采用GOIA—W（16，4）型脉冲信号，脉冲时长3．5ms，带宽20kHz，振幅维度0．81kHz，回讯时间45ms。一组频域信号和两组空间信号由成像系统沿等密度螺旋线隔行扫描获得。在LAsER激发步骤之后，传统的相位编码手段（PhaseEncoding，PE）给出的每像素1cm3的数据被用作参照标准。在更短时间，同样或者更高空间解析度下，由螺旋采样方法获取的谱图被用于和PE手段获取的谱图进行对比。相关的生化指标水平由分析软件分析谱图获得，并用Bland—Ahman方法进行分析。结果在低空间解析度（每像素1cm3）条件下，螺旋采样获取医用三维核磁共振谱图的速度4倍于传统的椭圆相位编码方法。提高空间解析度至每像素0．39cm3，螺旋采样的速率仍是2倍于每像素1cm3条件下的椭圆相位编码方法。上述提及的螺旋采样成像技术所成的谱图中，信噪比（sNR）均〉5，依此可以判断谱图中生化物质能够被明显地从背景噪声中区分出来。像素点尺寸减小导致的信噪比损失并非线性，因为缩小像素点尺寸需要延长T2阶段。在高空间解析度下，谱图中谱线的宽度由4．8Hz提高至3．5Hz。使用Bland—Ahman方法对螺旋采样和PE的成像结果进行分析，结论为二者之间相互吻合：二者的相似程度为95％（均值分别为0．12和0．18）。GIOA—W（16，4）型脉冲信号的使用有效地将化学位移误差降低至2．1％，并把激发过程的不一致度降低至5％，而且可以降低其他干扰抑制技术的需求。结论上述绝热螺旋采样三维MRI技术可以通过标准的MRI系统实现。该手段能够给予更高的成像质量和更短的成像时间，与现有技术相比能够保障更多的日常核磁共振数据的收集。

关键词：核磁共振光谱采样方法成像系统三维神经系统绝热核磁共振谱图患者知情同意

Inactivation of Air-suspended-Cells Through Ion Energy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

材料科学与工程（中英文A版） 2022年第3期12卷 81-86页

作者： Manuel borja salin Roger Bartolo Alarcon Claudia Paniagua Homobono Daniel Morales Diaz Enoc Espinosa Farias sergio Flores Gonzalez Darío Hernández Escalera Hilda Moreno saavedra Chemical Engineering Department National Technological Institute of MexicoTechnological Institute of TolucaMetepecEdo de México Mechatronic Engineering Department National Technological Institute of MexicoTechnological Institute of TolucaMetepec Edo de México Postgraduate studies and Research Division Metepec Edo de MéxicoCp.52149México

Cold plasma at room temperature and pressure is an emerging and novel tool for the inactivation of cell derived from its ionic energy,which is capable of breaking bonds such as carbon-carbon,carbon-hydrogen,carbon-oxygen,among others,these being the ones that support the biological structure of *** work tries to create its own infrastructure that includes a high voltage source,an infrared trigger which reduces the effect of the ozone created,an ionic reactor in which the plasma acts at atmospheric temperature and pressure,and a magnetic field that allow aligning the plasma to the combined processes that are carried out.

关键词： Cold plasma at room temperature and pressure inactivation of cells ionic energy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

GAN地毯系列:带你玩转几何

现代装饰 2019年第11期 182-183页

作者： borja García Enblanc Javier Tortosa Front Flavia del Pra 郭映琴

众所周知,几何是所有生命的数学基础。对于建筑师和室内设计师来说,当面临一个空白的空间时,最有用的工具之一就是几何学。几何学能够在混乱的表面中创造出秩序,它是一种整合任何项目中无序元素的方法。多年以来,GAN与许多设计师进行合... 详细信息

众所周知,几何是所有生命的数学基础。对于建筑师和室内设计师来说,当面临一个空白的空间时,最有用的工具之一就是几何学。几何学能够在混乱的表面中创造出秩序,它是一种整合任何项目中无序元素的方法。多年以来,GAN与许多设计师进行合作,将几何作为核心元素的潜力,不论是在产品还是整个空间的排布上,都发挥得淋漓尽致。本期与各位读者分享GAN系列地毯,带你玩转几何的奥妙。

关键词：室内设计师几何学核心元素玩转地毯建筑师

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

扩散边界:R.I.房屋

世界建筑导报 2019年第2期34卷 34-37页

作者： Adrian Moreno María samaniego Jorge Durán María Gracia borja Andrea Cisneros Bicubik sebastián Crespo Andrés Fernández

该项目中的房屋设计是在建造过程中逐渐形成的,在施工中确定当前的结构,而最终用途还未确定。客户家庭期待建成的建筑物,可让他们在周末的时候享受这个风景秀丽之地,远离城市喧嚣,但不确定是要建一个具有野外烧烤功能的凉亭、周末小屋... 详细信息

该项目中的房屋设计是在建造过程中逐渐形成的,在施工中确定当前的结构,而最终用途还未确定。客户家庭期待建成的建筑物,可让他们在周末的时候享受这个风景秀丽之地,远离城市喧嚣,但不确定是要建一个具有野外烧烤功能的凉亭、周末小屋、第二套住宅还是另一个办公室。

关键词：房屋设计扩散建造过程烧烤功能建筑物办公室施工凉亭

CXCR4+ and sDF-1+ Bone Marrow Cells Are Mobilized into the Blood stream in Acute Myocardial Infarction and Acute Ischemia

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Cardiovascular Diseases 2014年第7期4卷 361-367页

作者： Jose Luis Aceves Rafael Vilchis Maria Antonieta Medina Monserrat borja silvia Cortes Guillermo Diaz Armando Castro Alexis Gomez Jose JParra Martha Alvarado Manuel Lopez Hernandez Virna Poveda Felipe Masso Luis FMontano Division de Cardiocirugia Centro Medico Nacional 20 de Noviembre ISSSTEMexico DFMexico Departamento de Hematologia Centro Medico Nacional 20 de Noviembre ISSSTEMexico DFMexico Laboratorio de Hormonas Centro Medico Nacional 20 de Noviembre ISSSTEMexico DFMexico Departamento de Inmunobiologia Biologia Celular y Tisular Facultad de Medicina UNAMMexico DFMexico

Cell therapy has shown beneficial effects on ventricular function and tissue regeneration in patients with acute and chronic myocardial infarction, although with diverse grades of variability in the results, possibly by proportion, subtype and cell cycle status. Objective: Identify and phenotypically characterize, via CXCR4 and sDF-1 expression, the bone marrow cell subpopulations that are mobilized into the bloodstream in patients with Acute Myocardial Infarction (AMI) and Acute Ischemia (AI) such as acute angina and Chronic Ischemia (CI) such as chronic stable angina, and also determine the cell cycle status of these cells. Method: Patients with AMI and AI were recruited in the ICCU, and patients with CI in the departments of cardiology and cardiovascular surgery. The quantification of cellular subpopulations was made by cytofluorometry with a FACs caliburcyto fluorometry (Becton Dickinson) with specific FITC-labeled anti human monoclonal antibodies against CD34, CD133, CD117, CD48, CXCR4, sDF-1 and Ki67 (Becton Dickinson). serum concentration of IL-6 and IL-8 were determined by a sequential solid phase chemiluminescent assay performed in a sIEMENs IMMULITE 1000 Analyzer. statistical analysis was made with the sPss version 20.0 for Windows. A p value 3/ml) than that in AI (9.2 ± 1.3 × 103/ml) and CI (6.6 ± 1.1 × 103/ml) patients (p p = 0.22 to 0.39), but interestingly in AMI and AI patients, cells were CXCR4+ in almost half of these mobilized cells, although the proportion was significantly higher in AMI patients (46.8% ± 7.1% to 55.7% ± 6.3% vs 23% ± 1.6% to 28.4% ± 2.1%, p = 0.03 to 0.05). A similar behavior was observed with the Ki67 antibody (29.9% ± 2.1% to 36.1% ± 6.3% vs 10% ± 1.2% to 24% ± 1.1%, p = 0.001 to 0.05). Bivariate analysis of the results showed a significant correlation of the cell proportion in AMI but not in AI and CI patients (p = 0.001 to 0.05;0.12 to 0.87 and 0.17 to 0.92 respectively). The amount of myocardial tissue infarcted did not show

关键词： stem Cells CXCR4:sDF-1 Axis Cardiac Repair Acute and Chronic Ischemia

Immunomodulatory therapy for the management of critically ill patients with COVID-19:A narrative review

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Critical Care Medicine 2022年第4期11卷 269-297页

作者： David Andaluz-Ojeda Pablo Vidal-Cortes Álvaro Aparisi sanz borja suberviola Lorena Del Río Carbajo Leonor Nogales Martín Estefanía Prol silva Jorge Nieto del Olmo JoséBarberán Ivan Cusacovich Department of Critical Care Hospital Universitario HM SanchinarroHospitales MadridMadrid 28050Spain Department of Intensive Care Complejo Hospitalario Universitario de OurenseOurense 32005Spain Department of Cardiology Hospital del MarBarcelona 08003Spain Department of Intensive Care Hospital Universitario Marqués de ValdecillaSantander 39008Spain Department of Intensive Care Hospital Clínico Universitario de ValladolidValladolid 47005Spain Department of Internal Medicine Hospital Universitario HM MontepríncipeHospitales MadridBoadilla del Monte 28860MadridSpain Department of Internal Medicine Hospital Clínico Universitario de ValladolidValladolid 47005Spain

BACKGROUND severe acute respiratory syndrome coronavirus 2(sARs-CoV-2)is the causative agent of the ongoing coronavirus disease 2019(COVID-19)*** the physiological and immunological processes underlying the clinical manifestations of COVID-19 is vital for the identification and rational design of effective *** To describe the interaction of sARs-CoV-2 with the immune system and the subsequent contribution of hyperinflammation and abnormal immune responses to disease progression together with a complete narrative review of the different immunoadjuvant treatments used so far in COVID-19 and their indication in severe and life-threatening *** A comprehensive literature search was *** reviewed the selected manuscripts following the PRIsMA recommendations for systematic review and meta-analysis documents and selected the most ***,a recommendation of the use of each treatment was established based on the level of evidence of the articles and documents *** recommendation was made based on the consensus of all the *** A brief rationale on the sARs-CoV-2 pathogenesis,immune response,and inflammation was *** usefulness of 10 different families of treatments related to inflammation and immunopathogenesis of COVID-19 was reviewed and ***,based on the level of scientific evidence,a recommendation was established for each of *** Although several promising therapies exist,only the use of corticosteroids and tocilizumab(or sarilumab in absence of this)have demonstrated evidence enough to recommend its use in critically ill patients with *** including both,clinical and biological characteristics can constitute specific targets for better select certain therapies based on an individualized approach to treatment.

关键词： COVID-19 Critically ill patients Treatment Immunomodulary drugs Phenotype Immunosupression

平坦部玻璃体切割联合气体充填术治疗人工晶状体眼孔源性视网膜脱离下方裂孔

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

美国医学会眼科杂志（中文版） 2006年第2期18卷 81-84页

作者： Vicente Martinez-Castillo Alicia Verdugo Anna Boixadera José Garcga-Aruml borja Corcostegui 刘萍（译）蒋幼芹（校） Vall d' Hebrón Hospital Universidad Autónoma de Barcelona Instituto Oftalmológico de Barcelona Vall d' Hebrón Hospital Universidad Autónoma de Barcelona Instituto de Microcirugía Ocular Barcelona Spain Instituto de Microcirugía Ocular and Barcelona Spain

目的：判定不联合巩膜外加压的平坦部玻璃体切割术联合气体作24小时俯卧位填充物，在治疗原发性人工晶状体眼孔源性视网膜脱离下方裂孔的作用。方法：前瞻性、非比较性、干预病例系列。15只眼（15位患者）伴有4点钟至8点钟方位原发裂孔... 详细信息

目的：判定不联合巩膜外加压的平坦部玻璃体切割术联合气体作24小时俯卧位填充物，在治疗原发性人工晶状体眼孔源性视网膜脱离下方裂孔的作用。方法：前瞻性、非比较性、干预病例系列。15只眼（15位患者）伴有4点钟至8点钟方位原发裂孔的原发性人工晶状体眼孔源性视网膜脱离，行气体充填的平坦部玻璃体切割术。术后保持24小时俯卧位。本文报道了解剖性与功能性复位的结果。结果：一次手术后解剖复位率为93％。6个月随访时为100％。术前平均最佳矫正视力为20／60（范围，20／400至20／25），平均术后最佳矫正视力为20／30（范围，20／100至20／20）。有一例由于未检查到的裂孔，术后第2周视网膜再次脱离。一例术后观察到视网膜前膜。结论：用平坦部玻璃体切割联合气体填充术，术后仅24小时俯卧位治疗4到8点钟方位裂孔引起的原发性人工晶状体眼孔源性视网膜脱离卓有成效。

关键词：眼孔源性视网膜脱离玻璃体切割术人工晶状体气体充填卧位治疗裂孔充填术解剖复位率矫正视力

Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2021年第36期9卷 11285-11299页

作者： Jose María Huguet Xavier Cortés Marta Maia Bosca-Watts Marian Aguas Nuria Maroto Lidia Martí Cirilo Amorós Jose María Paredes Department of Gastroenterology General University Hospital of ValenciaValencia 46014Spain Department of Gastroenterology Hospital de SaguntoSagunto 46520Spain Department of Gastroenterology Hospital Clinico Universitario de ValenciaValencia 46010Spain Department of Gastroenterology Hospital Universitario y Politecnico la Fe de ValenciaValencia 46026Spain Department of Gastroenterology Hospital de ManisesManises 46940Spain Department of Gastroenterology Hospital Comarcal Francesc de BorjaGandia 46702Spain Department of Gastroenterology Hospital Arnau de Vilanova de ValenciaValencia 46015Spain Department of Gastroenterology Hospital Universitario Doctor Peset de ValenciaValencia 46017Spain

BACKGROUND In recent years,biological therapies have revolutionized the management of inflammatory bowel disease(IBD);however,they are *** development of biosimilar products has allowed us to reduce healthcare costs and improve patients’access to these *** various studies support the similarity between infliximab and its biosimilar CT-P13 in terms of efficacy and safety,there are unmet needs regarding research on these agents in the context of *** To analyze clinical response rates to CT-P13 and adverse events in IBD patients treated in real-life *** An observational,prospective,multicenter study of IBD patients treated with CTP13 in clinical practice who were naïve to biological treatments or failed to respond to other anti-tumor necrosis factor drugs or had switched from infliximab originator was carried *** diagnostic or follow-up interventions were conducted on patients outside usual clinical *** primary endpoints were clinical response rates and number of adverse *** primary efficacy variable was the proportion of patients who were in clinical remission and/or had a clinical response at 3,6,9,and 12 *** A total of 220 IBD patients treated with CT-P13(Remsima®)were included in the study:87(40%)with ulcerative colitis and 133(60%)with Crohn’s *** age of the patients was 41.47(sD 15.74)years,and 58%were ***(9%)patients started treatment with CT-P13 after switching from *** the remaining 201 patients,142(65%)were naïve to biologic *** baseline,68.6%(n=138/201)of patients presented with active *** 12 mo of treatment,14.8%(n=12/81)presented with active disease,and 64.2%(n=52/81)were in clinical remission without *** 3 mo,75.5%(n=115/152)had a clinical response or achieved clinical remission,which was sustained for 12 mo(85.2%;n=69/81).There was a decrease in specific IBD indices at 3,6,9,and 12 mo(Pse events

关键词： Crohn’s disease Ulcerative colitis Inflammatory bowel disease Infliximab Biosimilar CT-P13